[Asia Economy Reporter Myunghwan Lee] Inventage Lab announced on the 26th that it has received approval from the Australian Human Research Ethics Committee (HREC) for the clinical Phase 1 trial plan (IND) of 'IVL3004,' a long-acting injectable for the treatment of alcohol and drug addiction.
IVL3004 is a pipeline being developed as a once-monthly injectable by applying existing alcohol and drug addiction treatment ingredients to Inventage Lab's long-acting injectable development platform. Inventage Lab explained that it has drastically reduced the initial drug burst release, a chronic problem of existing long-acting injectables. They also added that it is expected to improve patient medication adherence by maintaining the same efficacy as existing injectables while improving side effects.
Inventage Lab plans to evaluate the safety, tolerability, and pharmacokinetic properties of IVL3004 in 30 subjects during this Phase 1 clinical trial.
Additionally, Inventage Lab explained that the patent barriers of the same ingredient product already approved by the U.S. Food and Drug Administration (FDA) can be circumvented through the 'IVL-DrugFluidic' manufacturing technology, which holds significant meaning in terms of development strategy. Through this, they expect to provide various treatment options to patients and medical professionals.
Joohee Kim, CEO of Inventage Lab, said, "With the approval of this clinical trial, a total of three pipelines, including the male pattern hair loss treatment (IVL3001) and dementia treatment (IVL3003), have entered the full-scale clinical development stage. We will do our best to accelerate the development of alcohol and drug addiction treatments, whose market is growing due to the ongoing serious social problems, and to achieve global commercialization success through successful clinical development."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
